PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Praxis Precision Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$260.17+18.41 (+7.61%)
Close on Oct 19, 2026
- Market cap
- $7.58B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$70.18 (+36.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Praxis Precision Medicines, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$305.38M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$378.17M
TTM Q2 2026
Free cash flow
-$305.38M
TTM Q2 2026
EPS, diluted
-$12.92
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $7.58B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.65
- Dividend yield
- –
- Free cash flow yield
- -4.03%
Fundamentals
- Revenue
- $0
- Net income
- -$339.13M
- EPS, diluted
- -$12.92
- Free cash flow
- -$305.38M
- Book value per share
- $46.03
- Diluted shares
- 29M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$378.17M
Net income
-$339.13M
EPS, diluted
-$12.92
Free cash flow
-$305.38M
Reported periodTrailing twelve months